Skip to content

TDCS and Aphasia Therapy in the Acute Phase After Stroke

The Neuromodulatory Effect of Combined Transcranial Direct Current Stimulation (tDCS) with Aphasia Therapy in the Acute Phase After Ischemic Stroke

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03297450
Enrollment
1
Registered
2017-09-29
Start date
2017-10-02
Completion date
2018-03-30
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aphasia Following Cerebral Infarction

Brief summary

This study evaluates the neuromodulatory effect of combined tDCS and aphasia therapy in patients in the acute stage after stroke. Half of the participants will receive aphasia therapy and tDCS, the other half will receive aphasia therapy and sham-tDCS.

Detailed description

Aphasia is present in about one third of all stroke patients in the acute phase. The first few months after stroke, considerable spontaneous recovery is initiated, including neuronal plasticity and reorganization processes. Language recovery in aphasic stroke patients involves reorganization of brain functions. Longitudinal fMRI studies reveal that the right hemisphere shows increased activity at different times in the recovery process, but in the long-term is correlated with poorer performance. Left re-lateralization, if possible, seems to be the most effective in restoring language function. For a large subgroup of patients, aphasia therapy is not sufficient to resolve language deficits and not all patients are capable to endure intensive aphasia therapy. Therefore, non-invasive techniques (NIBS) such as transcranial direct current stimulation (tDCS) are currently explored as an add-on treatment to improve or accelerate therapy outcomes. tDCS is a painless and safe stimulation tool that modulates cortical excitability through weak polarizing currents (1 mA - 2 mA) between two electrodes. These weak currents are thought to induce a subthreshold shift of resting membrane potentials towards depolarization or hyperpolarization. The effects of stimulation depend on the polarity of the applied current relative to the axonal orientation. It has been found that tDCS not only triggers immediate aftereffects, but also long-lasting effects that persist beyond the stimulation time, even for up to 12 months. It was suggested that long-term potentiation (LTP) and long-term depression (LTD) might be responsible for these long-term effects, however the precise physiologic mechanisms of action are not yet fully understood.

Interventions

DEVICEtDCS

C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA

BEHAVIORALAphasia therapy

Based on linguistic tests, individualized aphasia therapy will be provided

DEVICESham-tDCS

tDCS during the first 20 minutes of aphasia therapy at an intensity of 0mA (Sham)

Sponsors

University Hospital, Ghent
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

aphasia therapy (45 minutes) in combination with (sham or real) tDCS (20 minutes)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed with mild-moderate aphasia (Token Test Score between 7 and 40) * Inclusion in the first few days after stroke (acute phase) * Age 18 - 85 years * Being right-handed * Mothertongue: Dutch * Able to undergo functional and specific linguistic testing and therapy in the acute phase following stroke * Imaging (CT or MRI) prior to inclusion (standard of care) * Signed Informed Consent

Exclusion criteria

* History of other diseases of the central nervous system, psychological disorders and (developmental) speech and or language disorders * Serious non-linguistic, cognitive disorders (as documented in the patients' medical history and inquired in anamneses) * Prior brain surgery * Excessive use of alcohol or drugs

Design outcomes

Primary

MeasureTime frameDescription
Change in naming performancebaseline, 1 week, 3 months, 6 monthsNaming performance will be assessed with the Boston Naming Test at baseline, immediately following therapy, and after 3 and 6 months
Change in Vital Parametersbaseline, 1 hour (each session)Blood pressure and heart rate will be measured before and after each session of treatment

Secondary

MeasureTime frameDescription
Change in tolerability (Visual analogue scale)baseline, 1 hour (each session)A Visual analogue scale will assess tolerability before and immediately after each session
Change in Spontaneous Speechbaseline, 1 week, 3 months, 6 monthsA Semi-standardized interview of the AAT will assess functional communication at baseline, immediately after therapy, and at 3 and 6 months
Change in ERPsbaseline, 1 week, 3 months, 6 monthsEvoked potentials will be measured at baseline, immediately after treatment and after 3 and 6 months

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026